Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study

Chou PP, Jeong C, Ma E, Roberts AM, Katz A, Nong Y, Yan MJ, Johnsen N, Armstrong AW. GLP-1RAs and cardiovascular risk reduction in hidradenitis[...]

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials

Alexis AF, Kircik L, Chovatiya R, Rice ZP, Soong W, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream for[...]

Emergency versus Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Health Care Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency versus Outpatient Care for Pediatric Atopic[...]